CTR20262661 Tislelizumab Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape.Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background.Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why CTR20262661 is a hot trial to watch

Esophageal Squamous Cell Carcinoma is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. CTR20262661 is notable because it evaluates Tislelizumab in a Phase 2 design while (RECIST)v1.1 ORR serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Randomized, masking is Open-label, and the intervention model is Parallel Assignment. Planned enrollment of 120 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary:(RECIST)v1.1 ORRNot reported in English
• Primary:Not reported in EnglishNot reported in English
• Secondary:RECIST v1.1 (PFS) (DOR) (DCR), (OS)Not reported in English
• Secondary::SKB500-ADC SKB500-TAb KL610348 PKNot reported in English
• Secondary::SKB500 (ADA)Not reported in English

Benchmark readouts in the surrounding field

• A Phase 2 Trial of Neoadjuvant Chemoradiation With Pembrolizumab Followed by Pembrolizumab With Lenvatinib in Esophageal/Gastroesophageal Junction Squamous Cell and Adenocarcinomas (Phase 2): pCR = 0 Participants
• Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002) (Phase 2): PFS(1-year): HR = 0.54(95.0% CI, 0.32 - 0.94); PFS(1-year): HR = 0.54(95.0% CI, 0.32 - 0.94)
• Immunotherapy-based total neoadjuvant therapy versus neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cancer: Interim results of a randomized phase 2 study. (Phase 2): pCR = 76.2 % ; pCR = 63.2 %

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor:connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Tislelizumab (Approved; PD-1); SKB-500 (Phase 2; CD276 x Top I); Cisplatin (Approved; DNA)

Company & Deal Intelligence context: Sichuan Kelun Botai Biomedicine Co., Ltd. — China — http://www.kelun-biotech.com

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

CTR20262661 is a focused lens on Esophageal Squamous Cell Carcinoma development. Its value will be determined by whether Tislelizumab can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis?Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.